Wuxi Beita Pharmatech Co., Ltd. (WBP) was registered and entered into Jiangyin High- New-Tech Entrepreneurship Park in November, 2008, and relocated into Jiangyin Yangtze Biomedical Accelerator in December, 2011. It was qualified for high and new-tech enterprise by Jiangsu Province in October, 2012.
WBP is the only and first producer of carbon-13 and carbon-14 isotope-labeled precursor compounds in China. The products are mainly used for labeling small medicine molecules, and biological active molecules, thereby performing pharmacokinetic, clinical research and disease detections, etc. The company's main businesses include:
1、Prepare and localize C13 stable isotope labeled precursor compounds and provide labeling services.
2、 Prepare and localize C14 radio-isotope labeled precursor compounds and provide labeling services.
3、Prepare, develop and localize C13 stable isotope labeled diagnostic reagents for detecting respiratory diseases, such as GMP Grade Urea -13C (the gold standard for H. pylori detection), etc.
4、Prepare, develop and localize C13 and stable isotope labeled internal standard diagnostic reagents for detecting diseases, such as isotope labeled amino acids and L-carnitine derivatives (for screening metabolic hereditary diseases of newborns-with LC-MS / MS MS method) .
The registration capital of WBP is 12-million yuan. It has newly established professional labs of 2,400 square meters equipped with synthetic devices and advanced analytic instruments, as well as a specially trained isotope labeling team.
Since its establishment, the company got various grants from governments, such as “Wuxi Returned Overseas Entrepreneurs Plan” supported by Wuxi City in 2008, “the Science and Technology Support Plan” supported by Jiangsu Province in 2011, and “The Science and Technology Innovative Small Business Fund” supported by the Ministry of Science and Technology of China in 2009. The company got 13 patents authorized; established hundreds of preparation processes for isotope labeled precursor compounds; developed over 50 kinds of stabile isotope-labeled small molecule drugs, most of them were domestic innovative, and part were international initiative. The products were sold to the companies, universities and research institutions of the United States, India and Europe, as well as China. They were all qualified with the qualifications of international standards.
WBP has paid great attention to cooperation and searched for win-win strategy. The company signed cooperation agreements with the Nuclear Power Institute of China, China Institute of Atomic Energy, Shanghai Medicilon, XenoBiotic Laboratories (Nanjing), Beijing Rechen Force, Cambridge isotope Laboratories (USA), and so on. So we can establish the solutions for solving the shortage supply problem of C14 and for filling the blank of GMP-Grade Urea-13C, and so on. Now, the company is performing localizations for its isotope labeled products, and welcomes your involvement by joining, investing, or cooperating.
The company's five-year goal is to build a base of research, development, production, supply and service of C14 and C13 isotope labeled compounds and technologies in China, promote the developments of new drug discovery, biotech, medical treatment, agriculture, environmental protection, chemistry and other industries domestically and internationally, and make greater contributions to life science and human health.